Thursday, April 09, 2020 11:39:29 AM
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 10:27:52 PM
- Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 11/05/2024 02:00:00 PM
- Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin • PR Newswire (US) • 11/04/2024 01:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/25/2024 08:43:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2024 08:16:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 12:40:16 PM
- Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available • PR Newswire (US) • 10/17/2024 12:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 12:30:19 PM
- Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 • PR Newswire (US) • 10/07/2024 12:30:00 PM
- Moleculin to Present at Two Upcoming Investor Conferences • PR Newswire (US) • 10/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:30:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:00:16 PM
- Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma • PR Newswire (US) • 09/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:31:07 PM
- Moleculin Participates in Virtual Investor "What this Means" Segment • PR Newswire (US) • 09/16/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:15:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/13/2024 08:15:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2024 08:04:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:15:12 PM
- Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma • PR Newswire (US) • 09/09/2024 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/03/2024 09:15:55 PM
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 01:15:00 PM
- Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar • PR Newswire (US) • 08/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:10:01 PM
- Moleculin Announces Closing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/19/2024 08:05:00 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM